TURKEL CATHERINE C. 4
4 · Novus Therapeutics, Inc. · Filed Sep 13, 2018
Insider Transaction Report
Form 4
TURKEL CATHERINE C.
Chief Development Officer
Transactions
- Purchase
Common Stock
2018-09-11$4.56/sh+17,048$77,671→ 61,567 total - Purchase
Common Stock
2018-09-12$5.02/sh+16,632$83,476→ 78,199 total
Holdings
- 805(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]This transaction was executed in multiple trades at prices ranging from $4.47 to $4.70. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $4.97 to $5.04. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.